Azka Ali1,2, Zhigang Xie3, Laura Stanko1,2, Edward De Leo4, Young-Rock Hong2,5, Jiang Bian2,6, Karen C Daily1,2. 1. Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA. 2. University of Florida Health Cancer Center, Gainesville, FL, USA. 3. Division of Hematology & Oncology, Department of Internal Medicine, University of Florida, 1600 SW Archer Road, M401, Gainesville, FL, 32610, USA. 4. Division of Hematology & Oncology, Department of Internal Medicine, University of Florida, 1600 SW Archer Road, M401, Gainesville, FL, 32610, USA. Edward.deleo@medicine.ufl.edu. 5. Department of Health Services Research, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA. 6. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract
PURPOSE: Breast cancer in men (BC-M) is almost exclusively hormone receptor positive. We conducted a large review of the SEER-Medicare linked database to compare endocrine therapy adherence, discontinuation, and survival outcomes of male versus female patients with breast cancer. METHODS: Study data were obtained through the SEER-Medicare linked database. The study included patients age ≥ 65 years-old diagnosed with breast cancer between 2007 and 2015. The primary endpoints were rates of adherence and discontinuation of endocrine therapy (ET). Adherence was defined as a gap of less than 90 days in-between consecutive Medicare prescriptions. Discontinuation was defined as a gap of greater than 12 months in-between Medicare prescriptions. Secondary endpoint was the association of use of ET with overall survival (OS). RESULTS: Of the 363 male patients on ET, 214 patients (59.0%) were adherent to the therapy, and 149 patients (41.0%) were nonadherent. Of the 20,722 females on ET, 10,752 (51.9%) were adherent to the therapy, and 9970 (48.1%) were nonadherent. 39 male patients (10.7%) discontinued therapy, while 324 (89.3%) did not discontinue therapy. 1849 female patients (8.9%) discontinued therapy, while 18,873 (91.1%) patients did not. Men were significantly more adherent than women (p = 0.008), but there was no significant difference in discontinuation among men and women (p = 0.228). Survival was significantly improved in both men (HR 0.77, 95% CI 0.60-0.99, p = 0.039) and women (HR 0.84, 95% CI 0.81-0.87, p < 0.001) on ET. CONCLUSION: Identification of contributing factors impacting adherence and discontinuation is needed to allow physicians to address barriers to long term use of ET.
PURPOSE: Breast cancer in men (BC-M) is almost exclusively hormone receptor positive. We conducted a large review of the SEER-Medicare linked database to compare endocrine therapy adherence, discontinuation, and survival outcomes of male versus female patients with breast cancer. METHODS: Study data were obtained through the SEER-Medicare linked database. The study included patients age ≥ 65 years-old diagnosed with breast cancer between 2007 and 2015. The primary endpoints were rates of adherence and discontinuation of endocrine therapy (ET). Adherence was defined as a gap of less than 90 days in-between consecutive Medicare prescriptions. Discontinuation was defined as a gap of greater than 12 months in-between Medicare prescriptions. Secondary endpoint was the association of use of ET with overall survival (OS). RESULTS: Of the 363 male patients on ET, 214 patients (59.0%) were adherent to the therapy, and 149 patients (41.0%) were nonadherent. Of the 20,722 females on ET, 10,752 (51.9%) were adherent to the therapy, and 9970 (48.1%) were nonadherent. 39 male patients (10.7%) discontinued therapy, while 324 (89.3%) did not discontinue therapy. 1849 female patients (8.9%) discontinued therapy, while 18,873 (91.1%) patients did not. Men were significantly more adherent than women (p = 0.008), but there was no significant difference in discontinuation among men and women (p = 0.228). Survival was significantly improved in both men (HR 0.77, 95% CI 0.60-0.99, p = 0.039) and women (HR 0.84, 95% CI 0.81-0.87, p < 0.001) on ET. CONCLUSION: Identification of contributing factors impacting adherence and discontinuation is needed to allow physicians to address barriers to long term use of ET.
Authors: Vincent O Dezentjé; Nico J C van Blijderveen; Hans Gelderblom; Hein Putter; Myrthe P P van Herk-Sukel; Mariel K Casparie; Antoine C G Egberts; Johan W R Nortier; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2010-04-12 Impact factor: 44.544
Authors: F Cardoso; J M S Bartlett; L Slaets; C H M van Deurzen; E van Leeuwen-Stok; P Porter; B Linderholm; I Hedenfalk; C Schröder; J Martens; J Bayani; C van Asperen; M Murray; C Hudis; L Middleton; J Vermeij; K Punie; J Fraser; M Nowaczyk; I T Rubio; S Aebi; C Kelly; K J Ruddy; E Winer; C Nilsson; L Dal Lago; L Korde; K Benstead; O Bogler; T Goulioti; A Peric; S Litière; K C Aalders; C Poncet; K Tryfonidis; S H Giordano Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Anne Marie Bak Jylling; Vibeke Jensen; Giedrius Lelkaitis; Peer Christiansen; Sarah Schulz Nielsen; Marianne Djernes Lautrup Journal: Breast Cancer Date: 2020-02-27 Impact factor: 4.239
Authors: P Chalela; E Munoz; D Inupakutika; S Kaghyan; D Akopian; V Kaklamani; K Lathrop; A Ramirez Journal: Contemp Clin Trials Commun Date: 2018-10-17